Bridging the gap between makers and buyers
We are a social enterprise committed to improving health in low- and middle-income countries.
We broker partnerships that remove barriers stopping lifesaving medical innovations reaching people who need them.
Our agreements with makers and buyers across the health ecosystem speed up access to healthcare. We shoulder financial risk to strengthen health markets, enabling more products to reach more people more quickly.
We accelerate access to lifesaving products
Advances in medical science mean that many illnesses that would have been fatal just a few years ago can now be prevented, treated and cured.
But for millions of people around the world, these advances are either unavailable or unaffordable.
Unequal access to medical innovation leads to millions of preventable deaths every year. Too often, the people with the least resources are forced to wait years, or even decades, for the health products they need.
We believe people should have access to effective medical innovations when they need them, no matter where they live.
Putting everyone on a more equal footing
We are helping to make vaccines, diagnostics, treatments and other health technologies more affordable and available for people in low- and middle-income countries.
So far, our agreements have enabled medical innovations to reach more than 375 million people in over 90 countries.
By securing lower prices for products, we are helping procurers to save money, which can be used to tackle other urgent health needs.
Because fair access is at the heart of a healthier future
Since our foundation in 2017, we have secured nine agreements to increase access to health products. Our agreements are helping to tackle HIV, tuberculosis, malaria, syphilis and COVID-19.
All our agreements support strong partnerships that include businesses, global health organisations, countries, and civil society. We strongly believe that partnership is at the heart of transformational and sustainable health impact.
We are also aiming to expand our work to tackle non-communicable diseases, such as cancer and diabetes. We believe we can make a significant impact on the growing burden of non-communicable diseases in low- and middle-income countries, helping millions more people to live longer, healthier lives.
We were founded by British International Investment (BII), the UK’s development finance institution. BII is our anchor investor, with $200 million paid-in capital.
In 2021, the UK’s Foreign, Commonwealth & Development Office (FCDO) provided us with a £7.3 million grant as part of its Global Fund accelerator.
British International Investment
Foreign, Commonwealth & Development Office
28 November 2022
Five key lessons from our first five years
We’ve learned a lot in our first five years. When MedAccess was formed in 2017, we knew that financial guarantees could accelerate access to medical innovations for millions of people. But as the first social enterprise focused entirely on using innovative finance to increase access to healthcare, we’ve also learned more about how to use our tools most effectively and where we can broaden our impact.Five key lessons from our first five years
Find out more about our partnerships by reading our press releases, news stories and insight articles.Latest news
7 March 2023
One test, two results: How a dual test is tackling HIV and syphilis
19 December 2022
Price reduction paves the way for expanded access to highly effective multidrug-resistant tuberculosis treatment
15 March 2023
MedAccess welcomes WHO recommendation for chlorfenapyr-pyrethroid mosquito nets
MedAccess welcomes the World Health Organisation’s (WHO’s) strong recommendation for countries to use mosquito nets containing two insecticides – chlorfenapyr and pyrethroid. The recommendation follows two major trials – in Benin and Tanzania – that both found that nets that contained both insecticides were significantly more effective at preventing malaria cases than standard pyrethroid-only nets. MedAccess supported access to BASF’s …Read moreRead more